7 June 2022 in Environmental DNA
Vegetation is an underutilized medium for environmental DNA (eDNA) sampling. eDNA methods leveraging water as a substrate exclude application to many terrestrial species. The use of eDNA to detect small mammals can complement current survey approaches (live capturing, track plating, and camera trapping) while reducing risks to the animals. The endangered New Mexico meadow jumping mouse (Zapus hudsonius luteus) is specialized to herbaceous riparian zones, making it an ideal candidate for developing a terrestrial eDNA detection method. We developed a species‐specific assay for quantitative real‐time PCR, then tested the long‐term persistence of jumping mouse eDNA on plant material using four herbaceous day nests collected three to six months after occupancy. We conducted a field trial using sterile cotton swabs at six locations along two occupied streams to evaluate our assay's capability to detect present‐day eDNA. Each of 60 swabs was used to swab a 0.50 m2 area along streamside transects that included vegetation such as forbs, grasses, and sedges. We also opportunistically swabbed plants (n = 9) following visual observation of jumping mice. We determined the limit of detection for both assays are fewer than eight copies per reaction. We detected eDNA in three of four nests. From field trial samples, we successfully detected the species from randomly swabbed vegetation (N = 3), and four of nine swabs from vegetation recently used by individuals. Further work is required to develop a robust survey method using this eDNA detection approach. Our study demonstrated that mammalian eDNA can persist on nest vegetation long after the animal was present, highlighting the promise of using eDNA from plants to detect rare or endangered terrestrial species.
26 January 2026 in Clinical Cancer Research
Purpose: Androgen receptor pathway inhibitors (ARPI), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance and most eventually acquire secondary resistance. This study aimed to define genomic features of ARPI resistance using longitudinal ctDNA analysis. Experimental Design: We used the targeted AR-ctDETECT cell-free DNA (cfDNA) sequencing assay to profile tumor-derived genomic alterations in plasma samples collected at baseline and progression from patients with mCRPC enrolled in the phase III Alliance A031201 trial of first-line enzalutamide with or without abiraterone. Analysis focused on 327 patients with paired samples available from both time points. Results: Progression plasma samples displayed elevated cfDNA levels and increased ctDNA positivity. AR was the most frequently altered gene at baseline and at progression. AR copy-number gains and AR genomic structural rearrangements (AR-GSR) increased at progression, along with copy-number losses of FANCA, POLD1, RAD54L, CDKN2A, ZNRF3, and ETS2. An AR extrachromosomal DNA signature was enriched at progression and was associated with AR-GSRs predicted to truncate the AR ligand-binding domain. Stratification by two extre mes of radiographic progression-free survival revealed preferential accumulation of AR alterations in patients with delayed progression and a higher burden of non-AR alterations in patients with rapid progression. Conclusions: AR alterations in ctDNA accumulate at progression in patients with mCRPC treated with ARPIs, especially in those with initially durable responses. These findings support the use of liquid biopsy to serially track resistance mechanisms and inform precision therapy in advanced prostate cancer. See related commentary by Chauhan et al., p. 2323
3 January 2025 in Endocrine-Related Cancer
Treatment for castration-resistant prostate cancer (CRPC) primarily involves suppression of androgen receptor (AR) activity using androgen receptor signaling inhibitors (ARSIs). While ARSIs have extended patient survival, resistance inevitably develops. Mechanisms of resistance include genomic aberrations at the AR locus that reactivate AR signaling or lineage plasticity that drives emergence of AR-independent phenotypes. Given the diverse mechanisms of ARSI resistance in CRPC, there is a need for more effective monitoring strategies that detect signs of resistance to inform prognosis and guide use of alternative therapies. Liquid biopsy is a blood test that has emerged as a powerful, minimally invasive tool for investigating advanced cancer. In CRPC, liquid biopsy has been shown to reflect genomic and transcriptomic features in tumor tissue and has been utilized to detect an array of resistance signatures. Liquid biopsy is uninhibited by spatial restrictions and allows for longitudinal monitoring of disease progression. However, current clinical liquid biopsy tests provide limited actionable information. This review highlights recent advancements to the understanding of mechanisms driving treatment resistance in CRPC through research-grade liquid biopsy assays. We explore novel methods of disease characterization developed using liquid biopsy and emphasize the clinical potential of a multi-omics molecular profiling approach to comprehensively detect emerging therapeutic resistance. Routine assessment of therapy resistance using a liquid biopsy assay has the potential to enhance prognostication and improve outcomes of men with CRPC.